Empowering gene therapy, Medicilon and ZY Therapeutics reach a strategic collaboration

       On June 28, 2022, Shanghai Medicilon Inc. (Medicilon) and ZY Therapeutics Inc. (ZY) signed a strategic collaboration on preclinical IND application services to jointly promote development of gene therapy drugs.

ZY Therapeutics Inc. is a company focused on the development of biological and chemical drug delivery technologies, located in Research Triangle Park, North Carolina, USA.  ZY has achieved breakthrough results in the body delivery research of nucleic acid drugs (mRNA/siRNA/DNA), and has a rich cell and gene therapy product pipeline.  ZY's unique cationic lipid nano-formulations, in vivo plasmid DNA delivery, nano-targeted drug delivery and other platforms have applied for and authorized patents to protect global rights and interests.  The delivery technology of ZY's poorly soluble anticancer drug has also been approved by the US regulatory authorities.  ZY has also established pipelines such as innovative polysaccharide carriers to deliver tumor drugs and albumin-bound modified injections.  Guanhao Biotech Co., Ltd. (stock code: 300238), a Chinese GEM listed company, is the main shareholder of ZY Therapeutics Inc.东。

    Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China.  Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research.  Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support.  By the end of 2021, Medicilon has provided new drug R&D services to more than 1,460 clients around the world, and participated in the R&D of 221 new drug projects that have been approved for clinical trials.  Medicilon is proud to contribute to human health in the globe.！